Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934906 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL29457703 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL6933968 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL6557492 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL4575410 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL232128 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL4576328 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL232384 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL232385 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD | |
| SCHEMBL12019442 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2OPRD1CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158016-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | claimed |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-09-17 | — | — | US | claimed |
| EP-3432884-A1 | COMBINATION FOR TREATING PAIN | Regents of the University of Minnesota (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2017165558-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-09-28 | — | — | WO | claimed |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-05 | — | — | US | claimed |
| US-6300332-B1 | DRUG MEDIATED RESPIRATORY DEPRESSION, MUSCLE RIGIDITY AND NAUSEA/VOMITING AND SIDE EFFECT REDUCTION | DELTA PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | claimed |
| EP-4704874-A2 | MOLECULES AND METHODS OF USE THEREOF | Woolwich Sciences LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | TEIKOKU PHARMA USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4608374-A1 | METHODS AND COMPOSITIONS COMPRISING FLT3L FOR THE TREATMENT OF WOUNDS | The University of Chicago (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| EP-1003373-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5985880-A | REDUCING, TREATING OR PREVENTING DRUG-MEDIATED RESPIRATORY DEPRESSION IN AN ANIMAL BY ADMINISTERING A .DELTA. RECEPTOR AGONIST COMPOUND | DELTA PHARMACEUTICALS (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999001033-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| US-5854249-A | Opioid diarylmethylpiperazines and piperidines | DELTA PHARMACEUTICALS, INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5658908-A | RECEPTOR BINDING SPECIES FOR MEDIATING ANALGESIA, COMBATTING DRUG ADDICTION, DRUG OVERDOSE | DELTA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0649414-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-26 | — | — | EP | disclosed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158016-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY | OPRD1, OPRM1, OPRK1 | CYP3A4 3601/4885CYP1A2 2525/4885OPRD1 1/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | CYP3A4 2837/4885CYP1A2 2618/4885OPRD1 4518/4885 |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | OPRD1, OPRK1, OPRM1 | CYP3A4 656/4885CYP1A2 249/4885OPRD1 1/4885 |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | OPRL1, ACHE, OPRK1 | CYP3A4 2957/4885CYP1A2 1796/4885OPRD1 6/4885 |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | BIRC5, MTX2, IAPP | CYP3A4 771/4885CYP1A2 493/4885OPRD1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.